Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

One specific type of viral exanthem that dermatologists have seen with COVID is a morbilliform rash, meaning a measles-like rash. Measles rashes tend to look like small raised bumps that eventually ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna Inc. delivered better-than-expected profit and sales in the third quarter after an early start to sales of this ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

On Thursday, Moderna Inc (NASDAQ:MRNA) stock is trading higher after the company reported better-than-expected third-quarter ...

After accounting for the 9 per cent tax charge, the group’s profit after tax is AED 9.3 billion (€2.3 billion). Photo: Fergal ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Moderna’s sales will be hit by slowing vaccine uptake, analysts said as they slashed the target price for the drug maker by ...